Published in Clin Exp Immunol on April 01, 1991
Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J (1994) 3.68
Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. Am J Transplant (2014) 2.09
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Invest (1999) 1.32
Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol (2008) 1.31
Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun (1998) 1.24
Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin Exp Immunol (1993) 1.21
Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol (2004) 1.11
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology (2008) 1.06
Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) (2009) 1.03
Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. J Exp Med (1996) 1.03
Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Semin Immunopathol (2007) 1.02
Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes. Immunology (1994) 0.97
Recombinant human IgA expressed in insect cells. Proc Natl Acad Sci U S A (1994) 0.97
Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci U S A (2012) 0.96
IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med (2007) 0.94
A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes. Clin Exp Immunol (1995) 0.93
Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax. Infect Immun (2010) 0.91
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med (2015) 0.90
Hyper-immunoglobulin G2 production by B cells from patients with localized juvenile periodontitis and its regulation by monocytes. Infect Immun (1996) 0.90
An acute model for IgA-mediated glomerular inflammation in rats induced by monoclonal polymeric rat IgA antibodies. Clin Exp Immunol (1993) 0.89
In vivo activation of complement by IgA in a rat model. Clin Exp Immunol (1992) 0.88
Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation. Biophys J (2007) 0.87
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol (2013) 0.87
The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA. Immunology (1994) 0.86
Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies. Clin Exp Immunol (1993) 0.85
Antibodies to actin in autoimmune haemolytic anaemia. BMC Vet Res (2010) 0.84
Complement activating properties of monoreactive and polyreactive IgM rheumatoid factors. Ann Rheum Dis (1993) 0.81
Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol (2012) 0.80
Regulation and targeting of T-cell immune responses by IgE and IgG antibodies. Immunology (1995) 0.80
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. PLoS One (2016) 0.79
Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring. Pediatr Nephrol (2006) 0.79
Abnormal immunoglobulin G subclass production in response to keyhole limpet haemocyanin in atopic patients. Clin Exp Immunol (1992) 0.79
Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J (2014) 0.79
Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG. J Clin Immunol (2000) 0.78
Secretory component (polymeric immunoglobulin receptor) as an intrinsic inhibitor of biological functions of interferon gamma in keratinocytes. Arch Dermatol Res (1995) 0.78
IgM-Dependent Phagocytosis in Microglia Is Mediated by Complement Receptor 3, Not Fcα/μ Receptor. J Immunol (2015) 0.77
Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection. PLoS Negl Trop Dis (2016) 0.76
Anti-tumor immunoglobulin M increases lung metastasis in an experimental model of malignant melanoma. Clin Exp Metastasis (2003) 0.76
Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS. PLoS One (2014) 0.75
Targeted FcγR mediated clearance by a biparatopic bispecific antibody. J Biol Chem (2017) 0.75
High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. Genome Med (2017) 0.75
Effect of complement on sizes of model immune complexes. Dokl Biochem Biophys (2014) 0.75
A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol (1966) 43.66
A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J Infect Dis (1959) 22.10
Activation of the alternate pathway of human complements by rabbit cells. J Immunol (1974) 5.59
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 3.57
The use of ammonium sulphate globulin precipitation for determination of affinity of anti-protein antibodies in mouse serum. Immunology (1972) 3.00
The role of complement and its receptor in the elimination of immune complexes. N Engl J Med (1986) 2.63
Two complement interaction sites in guinea pig immunoglobulins. J Immunol (1971) 1.92
Complement fixation by the F(ab')2-fragment of pepsin-treated rabbit antibody. Immunology (1971) 1.74
Physiological and pathological aspects of circulating immune complexes. Kidney Int (1989) 1.57
The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J Immunol (1988) 1.57
The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol (1983) 1.55
Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54
Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol (1987) 1.38
The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol (1989) 1.24
Heberden oration 1986. Complement--friend or foe? Br J Rheumatol (1987) 1.24
Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol Immunol (1988) 1.15
The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int (1987) 1.07
Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin Immunol Immunopathol (1987) 1.04
DNA/anti-DNA complexes: correlation of size and complement fixation. Arthritis Rheum (1981) 1.02
Classes and subclasses of rat antibodies: reaction with the antigen and interaction of the complex with the complement system. Immunology (1981) 0.96
Complement deficiency and the pathogenesis of autoimmune immune complex disease. Chem Immunol (1990) 0.93
Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptor. Clin Immunol Immunopathol (1984) 0.90
Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes. Scand J Immunol (1988) 0.84
BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells. Immunology (1988) 0.84
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Identification of Ss protein as murine C4. Nature (1975) 1.63
Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63
Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J (1976) 1.61
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60
The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol (1968) 1.58
Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. Int Arch Allergy Appl Immunol (1965) 1.56
Complement genetics in relation to HLA. Br Med Bull (1978) 1.55
Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54
A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50
The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43
Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasma in the serum. Clin Exp Immunol (1973) 1.42
Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology (1970) 1.42
Studies on the terminal stages of complement lysis. Immunology (1973) 1.40
Combined genetic deficiency of C6 and C7 in man. Clin Exp Immunol (1978) 1.38
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol (1978) 1.37
An iatrogenic autoantibody: immunological responses to 'pituitary snuff' in patients with diabetes insipidus. Clin Exp Immunol (1966) 1.35
Immunoconglutinins in human saliva--a group of unusual IgA antibodies. Immunology (1970) 1.35
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure (1994) 1.34
An improved purification procedure for the third component of complement and beta 1H globulin from human serum. Mol Immunol (1979) 1.34
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32
Immunity deficiency in pathogenesis of glomerulonephritis. Lancet (1974) 1.31
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology (2001) 1.31
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol (1990) 1.29
Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol (1976) 1.28
Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals. Ciba Found Symp (1986) 1.28
Allotypes of complement components in man. Transplant Rev (1976) 1.27
Inherited structural variation and linkage relationships of C7. J Immunogenet (1978) 1.26
Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25
Measles virus receptor on human T lymphocytes. Nature (1975) 1.24
The fractionation of antigen-dependent macrophage migration inhibition and macrophage activation factors from lymph draining a tuberculin reaction. Scand J Immunol (1974) 1.24
Inherited deficiencies of the terminal components of human complement. Immunodefic Rev (1992) 1.24
The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol (1993) 1.22
Lymphocyte cooperation. Proc R Soc Lond B Biol Sci (1971) 1.21
Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum (1988) 1.21
The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation. Eur J Immunol (1988) 1.18
Restoration of specific immunological virginity. Nature (1974) 1.16
Consent and confidentiality--where are the limits? An introduction. J Med Ethics (2003) 1.15
Cellular immunity in subacute sclerosing panencephalitis. Proc R Soc Med (1974) 1.14
Lesions due to complement in lipid membranes. Nature (1971) 1.13
Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest (1975) 1.11
The failure to show a necessary role for C3 in the in vitro antibody response. Eur J Immunol (1975) 1.08
Studies on antigenic competition. II. Abolition of antigenic competition by antibody against or tolerance to the dominant antigen: a model for antigenic competition. Immunology (1972) 1.08
Further studies on the C3b inactivator or conglutinogen activating factor (KAF). Immunochemistry (1973) 1.07
Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol (1997) 1.07
Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation. Biochem J (1988) 1.06
Bovine serum conglutinin is a lectin which binds non-reducing terminal N-acetylglucosamine, mannose and fucose residues. Biochem J (1989) 1.06
Novel cleavage products of the third component of human complement. Mol Immunol (1980) 1.05
Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur J Immunol (1997) 1.05
Inherited complement deficiencies. Philos Trans R Soc Lond B Biol Sci (1984) 1.04
Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. Immunology (1992) 1.03
Ultrastructure and composition of bovine conglutinin. Biochem J (1986) 1.02
Bovine conglutinin is a collagen-like protein. Biochemistry (1984) 1.02
C6: synthesis by the liver in vivo. J Exp Med (1977) 1.02
Streptococcal infection in young pigs. 3. The immunity of adult pigs investigated by the bactericidal test. J Hyg (Lond) (1969) 1.01
Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus. Arthritis Rheum (1987) 1.01
Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59. J Exp Med (1994) 1.01
Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clin Exp Immunol (1987) 1.01